Baicalein Inhibits the SMYD2/RPS7 Signaling Pathway to Inhibit the Occurrence and Metastasis of Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Lung cancer remains a leading cause of cancer-related mortality worldwide.
• Identifying novel therapeutic agents targeting cancer cell proliferation, migration, and invasion is crucial.
• Baicalein, a flavonoid, has shown potential anti-cancer properties in preliminary studies.

Purpose of the Study:

• To investigate the effects of Baicalein on the proliferation, migration, and invasion of human lung cancer cell lines (A549 and NCI-H1299).
• To elucidate the underlying molecular mechanisms, specifically focusing on the SMYD2/RPS7 signaling pathway.

Main Methods:

• Cell proliferation was assessed using MTT and clonogenesis assays.
• Cell migration and invasion were evaluated using Transwell assays.
• In vivo efficacy was determined using a subcutaneous transplanted tumor model in mice.
• The expression of the SMYD2/RPS7 signaling pathway was analyzed by quantitative real-time PCR (qRT-PCR).

Main Results:

• Baicalein significantly inhibited the proliferation of A549 and NCI-H1299 lung cancer cells in a dose-dependent manner.
• Baicalein treatment markedly reduced the invasion and clone formation rates of these cancer cells.
• Both SMYD2 and Baicalein demonstrated inhibitory effects on lung cancer tumor proliferation in vivo.
• Mechanism studies revealed that Baicalein downregulates the SMYD2/RPS7 signaling pathway.

Conclusions:

• Baicalein exhibits significant anti-proliferative, anti-migratory, and anti-invasive effects on human lung cancer cells.
• The observed anti-cancer effects of Baicalein are mediated through the inhibition of the SMYD2/RPS7 signaling pathway.
• Baicalein represents a promising therapeutic candidate for lung cancer treatment.